Impact of rotavirus vaccination in Australian children below 5 years of age: a database study

Annmarie Pendleton, Maja Galic, Christopher Clarke, Su Peing Ng, Emilio Ledesma, Gunasekaran Ramakrishnan, Yanfang Liu, Annmarie Pendleton, Maja Galic, Christopher Clarke, Su Peing Ng, Emilio Ledesma, Gunasekaran Ramakrishnan, Yanfang Liu

Abstract

This study was conducted to assess the impact of administration of two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines) among children aged less than 5 y in three states/territories of Australia. Aggregated and de-identified data on rotavirus gastroenteritis (RVGE) and all-cause gastroenteritis (AGE) from July 1998-June 2009 were obtained from the Australian Institute of Health and Welfare database. The baseline incidence (July 1998-June 2006) of RVGE hospitalizations before RV vaccine introduction in New South Wales (NSW), the Australian Capital Territory (ACT) and the Northern Territory (NT) were 33.75, 42.93 and 288.67 per 10,000 child-years, respectively among children aged 0-11 mo. Following RV vaccine introduction in NSW, the ACT and the NT, incidence of RVGE hospitalizations reduced to 13.06, 17.35 and 47.52 per 10,000 child-years, respectively, during July 2007-June 2008 and 3.87, 8.40 and 122.79 per 10,000 child-years, respectively, during July 2008-June 2009 among children aged 0-11 mo. Reductions in RVGE and AGE were also observed in all children below 5 y of age in NSW and the ACT. Overall reduction in hospitalizations due to RVGE and AGE was observed following RV vaccine introduction into the NIP in Australia.

Trial registration: ClinicalTrials.gov NCT01236066.

Keywords: Australia; gastroenteritis; hospitalization; incidence; rotavirus.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3906257/bin/hvi-9-1617-g1.jpg
Figure 1. Average monthly hospitalizations in NSW (July 1998 to June 2009).
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3906257/bin/hvi-9-1617-g2.jpg
Figure 2. Average monthly hospitalizations in the ACT (July 1998 to June 2009).
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3906257/bin/hvi-9-1617-g3.jpg
Figure 3. Average monthly hospitalizations in the NT (July 1998 to June 2009).

References

    1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565–72. doi: 10.3201/eid0905.020562.
    1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, WHO-coordinated Global Rotavirus Surveillance Network 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136–41. doi: 10.1016/S1473-3099(11)70253-5.
    1. Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Aust N Z J Public Health. 2006;30:416–21. doi: 10.1111/j.1467-842X.2006.tb00456.x.
    1. WHO. Wkly Epidemiol Rec 2007; 82:285-96. Accessed November 21, 2012 from: .
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. doi: 10.1056/NEJMoa052664.
    1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Human Rotavirus Vaccine Study Group Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434.
    1. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–98. doi: 10.1056/NEJMoa0904797.
    1. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757–63. doi: 10.1016/S0140-6736(07)61744-9.
    1. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009;27:5936–41. doi: 10.1016/j.vaccine.2009.07.098.
    1. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:615–23. doi: 10.1016/S0140-6736(10)60755-6.
    1. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:606–14. doi: 10.1016/S0140-6736(10)60889-6.
    1. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr. 2010;169:1379–86. doi: 10.1007/s00431-010-1242-3.
    1. Kirkwood CD, Boniface K, Bishop RF, Barnes GL. Australian Rotavirus Surveillance Program: annual report, 2009/2010. Commun Dis Intell Q Rep. 2010;34:427–34.
    1. Rotavirus vaccines for Australian children. 2009. Accessed November 21, 2012 from: .
    1. Barnes GL, Bishop RF. Rotavirus vaccine--time to act. Med J Aust. 2006;185:352–3.
    1. Hull BP, Deeks S, Menzies RI, McIntyre P. Immunisation coverage annual report, 2007. Commun Dis Intell Q Rep. 2009;33:170–87.
    1. Hull BP, Mahajan D, Dey A, Menzies RI, McIntyre PB. Immunisation coverage annual report, 2008. Commun Dis Intell Q Rep. 2010;34:241–58.
    1. Newall AT, MacIntyre R, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. J Paediatr Child Health. 2006;42:521–7. doi: 10.1111/j.1440-1754.2006.00915.x.
    1. The Australian Technical Advisory Group on Immunisation (ATAGI) and the National Health and Medical Research Council. (NHMRC) (2008) Australian Immunisation Handbook, 9th edition, 2008:265-73. Accessed November 21, 2012 from: .
    1. Macartney KK, Porwal M, Dalton D, Cripps T, Maldigri T, Isaacs D, et al. Decline in rotavirus hospitalisations following introduction of Australia’s national rotavirus immunisation programme. J Paediatr Child Health. 2011;47:266–70. doi: 10.1111/j.1440-1754.2010.01953.x.
    1. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(Suppl):S25–9. doi: 10.1097/INF.0b013e3181fefdee.
    1. Payne DC, Szilagyi PG, Staat MA, Edwards KM, Gentsch JR, Weinberg GA, et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J. 2009;28:948–53. doi: 10.1097/INF.0b013e3181a6ad6e.
    1. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis. 2010;201:1617–24. doi: 10.1086/652403.
    1. Schultz R. Rotavirus gastroenteritis in the Northern Territory, 1995-2004. Med J Aust. 2006;185:354–6.
    1. Webby R, Nagy C, Krause V, Darwin CDC. Childhood immunisation coverage and timeliness in the NT. The Northern Territory Disease Control Bulletin. 2009;16:12–5.
    1. Cook H, Krause V. A review of G2P[4] rotavirus outbreaks in Central Australia and how the introduction of Rotarix® has affected the epidemiology. The Northern Territory Disease Control Bulletin. 2010;17:14–21.
    1. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust. 2009;191:157–60.
    1. Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust. 2012;197:453–7. doi: 10.5694/mja12.10062.
    1. Riordan FA, Quigley T. Estimating hospital admissions due to rotavirus gastroenteritis from hospital episode statistics. J Infect. 2004;49:13–6. doi: 10.1016/j.jinf.2004.02.006.
    1. Hsu VP, Staat MA, Roberts N, Thieman C, Bernstein DI, Bresee J, et al. Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115:78–82.
    1. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR) Am J Epidemiol. 1990;131:373–5.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever